Cytokinetics Q4 net loss widens

-1.22%

Cytokinetics, Incorporated

CYTK

60.95

-1.22%

Overview

Cardiovascular biopharma's Q4 revenue rose yr/yr, driven by MYQORZO approvals
Net loss for Q4 widened compared to last year
Company holds $1.2 bln in cash, cash equivalents, and investments

Outlook

Cytokinetics projects 2026 GAAP combined R&D and SG&A expenses of $830 mln to $870 mln

Result Drivers

MYQORZO APPROVALS - Q4 revenue growth driven by MYQORZO approvals in U.S., China, and Europe, leading to milestone payments
EXPENSE INCREASES - Higher R&D and G&A expenses due to clinical trials and commercial readiness efforts

Company press release: ID:nGNX4dSwwf

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$183.03 mln
Q4 Basic EPS		-$1.50
Q4 Operating Expenses		$196.12 mln
Q4 Operating Income		-$178.37 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cytokinetics Inc is $88.00, about 28.9% above its February 23 closing price of $68.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.